Article

Peptidylarginine Deiminase 3 Modulates Response to Neratinib in HER2 Positive Breast Cancer

2024-04-22

Abstract excerpt

<title>Abstract</title> <p>Background Neratinib is a tyrosine kinase inhibitor that is used for the therapy of patients with HER2 + breast tumors. However, despite its clinical benefit, resistance to the drug may arise. Here we have created cellular models of neratinib resistance to investigate the mechanisms underlying such resistance. Methods Chronic neratinib exposure of BT474 human HER2 + breast cancer cell...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 956284ea-ce6a-5838-8511-257b03a108f1
DOI: 10.21203/rs.3.rs-4232081/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Peptidylarginine Deiminase 3 Modulates Response to Neratinib in HER2 Positive Breast CancerDOI 10.21203/rs.3.rs-4232081/v1Read

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4Semantic proximity Read

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Semantic proximity Read

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatmentsSemantic proximity Read

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.Semantic proximity Read

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.Semantic proximity Read

AGR2, a potential prognostic and predictive biomarker and therapeutic to overcome drug resistance in HER2-overexpressing cancerSemantic proximity Read

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsSemantic proximity Read

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast CancerSemantic proximity Read

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerSemantic proximity Read

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.Semantic proximity Read

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Semantic proximity Read